A Comparison of Ivermectin and Non Ivermectin Based Regimen for COVID-19 in Abuja: Effects on Virus Clearance, Days-to-discharge and Mortality

Y. Thairu

University of Abuja, Nigeria.

O. E. Babalola *

Bingham University, Nigeria.

A. A. Ajayi

Baylor College, Texas, USA.

Y. Ndanusa

Al Ummah Foundation, Abuja, Nigeria.

J. O. Ogedengbe

University of Abuja, Nigeria.

Omede O.

Federal Ministry of Health, Abuja, Nigeria.

*Author to whom correspondence should be addressed.


Aim: To compare outcomes from ivermectin (IVM) - and non-ivermectin (NIVM)-based treatments for COVID-19 in Abuja, Nigeria.

Methods: Sixty-one consecutive virology-proven cases were recruited and managed with IVM-based regimes. A subsequent cohort of 26 patients was treated with NIVM due to physician preference, with varying combinations of lopinavir/ritonavir (Alluvia), remdesivir, azithromycin, and enoxapramin. All patients received zinc sulfate, vitamin C and supportive therapy. Propensity matching was carried out as indicated, and Repeat Measures Analysis of Variance (RMANOVA) allowing for time*treatment interaction was carried out for time dependent variables, deriving Likelihood Ratio (LR) and P values.

Main Outcome Measures: Change in cycle threshold (viral load) over time, positivity status by day 5, improvement in clinical status using myalgia scores, days to discharge (DTD), change in SpO2 and death.

Results: IVM was associated with a greater and faster reduction in viral clearance (LR=64.2 p< 0.0001 for the N gene): 31% and 95% were negative by days 5 and 14, respectively, versus 0% on NIVM. The mean DTD on IVM was 8.8 days versus 19.4 days, p< 0.0001. IVM proved significantly superior for Myalgia scores, LR= 23.45, P=0.0007. The mortality rate was 0/61 (0%) in IVM but 4/26 (15.3%) in NIVM. Three of the 4 deaths were in females, and 2 had been vaccinated, one fully. The SP02% increased significantly more on IVM (p < 0.0001 RMANOVA) than the NIVM group. C-reactive protein and D-dimer levels dropped significantly more sharply during IVM (P= 0.0068, 0.063), suggesting anti-inflammatory and antifibrinolytic activity.

Conclusions: The IVM-based regimen caused earlier discharge from treatment and reduced mortality, in addition to clinical and laboratory improvements. Vaccination did not protect some patients from SARS-CoV-2 breakthrough infection and mortality.

Keywords: SARS-CoV-2, ivermectin, SpO2%, vaccination, mortality

How to Cite

Thairu, Y., Babalola, O. E., Ajayi, A. A., Ndanusa, Y., Ogedengbe, J. O. and O., O. (2022) “A Comparison of Ivermectin and Non Ivermectin Based Regimen for COVID-19 in Abuja: Effects on Virus Clearance, Days-to-discharge and Mortality”, Journal of Pharmaceutical Research International, 34(44A), pp. 1–19. doi: 10.9734/jpri/2022/v34i44A36328.


Download data is not yet available.